Discontinuation and long-term adherence to beta interferon therapy in patients with multiple sclerosis;Discontinuación y adherencia a largo plazo en la terapia con interferón beta en pacientes con esclerosis múltiple

Farmacia Hospitalaria

Volumn 36, Issue 2, 2012, Pages 77-83

  Vicente Iturbe, C ^a   Ara Callizo, J R ^a   Huarte Lacunza, R ^a   Navarro Aznarez H ^a   Serrano Mislata, N ^a   Rabanaque Hernandez M J ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Adherence; Compliance; Discontinuation; Interferon beta; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON;

AGED; ARTICLE; DATA BASE; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RELAPSE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 84858333740     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.1016/j.farma.2010.12.006     Document Type: Article

References (21)

1. N. Holland, P. Wiesel, P. Cavallo, C. Edwards, J. Halper, and R. Kalb Adherence to disease-modifying therapy in multiple sclerosis: Part I Rehabil Nurs 26 2001 172 176
2. N. Holland, P. Wiesel, P. Cavallo, C. Edwards, J. Halper, and R. Kalb Adherence to disease-modifying therapy in multiple sclerosis: Part II Rehabil Nurs 26 2001 221 226
3. WHO. Adherence to long-term therapies: evidence for action. Ginebra 2003.
4. K. Costello, P. Kennedy, and J. Scanzillo Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term Medscape J Med 10 2008 225 230
5. K. Treadaway Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 2009 568 576
6. E.M. Frohman, O. Stüve, E. Havrdova, J. Corboy, A. Achiron, and R. Zivadinov Therapeutic considerations for disease progression in multiple sclerosis Arch Neurol 62 2005 1519 1530
7. A.P. Ross, and Tolerability adherence and patient outcomes Neurology 71 Suppl3 2008 S21 S23
8. M. Hutchinson Treatment adherence: What is the best that can be achieved? Int MSJ 12 2005 73 (Pubitemid 41712023)
9. K.K. Daugherty, J.S. Butler, M. Mattingly, and M. Ryan Factors leading patients to discontinue multiple sclerosis therapies J Am Pharm Assoc 45 2005 371 375 (Pubitemid 46037299)
10. D.C. Mohr, D.E. Goodkin, L. Masuoka, L.P. Dick, D. Russo, and J. Eckhardt Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis Mult Scler 5 1999 192 197 (Pubitemid 29290449)
11. Gurtubay IG, Morales G, Gállego J, Martín E, Maraví E. Tolerancia al interferón beta-1b en pacientes con esclerosis múltiple remitente recurrente después de más de un año de tratamiento [Internet]. [consultado 27 marz 2007]. Disponible en: http://www.cfnavarra.es/salud/anales/textos/vol21/n1/orig1a.html.
12. M. Clerico, P. Barbero, G. Contessa, C. Ferrero, and L. Durelli Adherence to interferon-beta treatment and results of therapy switching J Neurol Sci 259 2007 104 108 (Pubitemid 47031209)
13. H. Tremlett, and J. Oger Adherence from across the pond: Six years of experience with beta-interferons for multiple sclerosis Pharm J 271 2003 649 653 (Pubitemid 37456161)
14. X. Nogués, M.L. Sorli, and J. Villar Instrumentos de medida de adherencia al tratamiento An Med Interna 24 2007 138 141
15. nd Congress of the European Committee for treatment and research in multiple sclerosis 2006 European Committee for treatment and research in multiple sclerosis (ECTRIMS) Madrid
16. K.E. O'Rouke, and M. Hutchinson Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns Mult Scler 11 2005 46 50 (Pubitemid 40259974)
17. E. Portaccio, V. Zipoli, G. Siracusa, S. Sorbi, and M.P. Amato Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis Eur Neurol 59 3-4 2008 131 135 (Pubitemid 351301255)
18. J. Rio, J. Porcel, N. Tellez, A. Sanchez-Betancourt, M. Tintore, and M.J. Arevalo Factors related with treatment adherente to interferon beta and glatiramer acetate therapy in multiple sclerosis Mult Scler 11 2005 306 309 (Pubitemid 40775187)
19. M. Sandberg-Wollheim, C. Bever, J. Carter, M. Färkkilä, B. Hurwitz, Y. Lapierre for the EVIDENCE Study Group Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis The EVIDENCE study J Neurol 252 2005 8 13 (Pubitemid 40179012)
20. S. Twork, I. Nippert, P. Scherer, J. Haas, D. Pöhlau, and J. Kugler Inmunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse events evaluation in a German multiple sclerosis population Curr Med Res Opin 23 2007 1209 1215 (Pubitemid 46998430)
21. D.C. Mohr, W. Likosky, A.C. Boudewyn, P. Marietta, P. Dwyer, and J. Van der Wende Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a Mult Scler 4 1998 487 489 (Pubitemid 29042155)